Podcasts

Rathore: What Biosimilar Developers Can Learn From Application Failures

July 26th 2020

Podcast

We sat down with Anurag Rathore, PhD, lead author of the study and coordinator of the Center of Excellence for Biopharmaceutical Technology in Delhi, India, to discuss the findings from this study and how biosimilar corporations can learn from them.

Byoungseo Choi on Celltrion's Biosimilar Goals For 2030

July 19th 2020

Podcast

We sat down with Byoungseo Choi, the head of marketing for Celltrion Healthcare, to discuss exactly how this plan is going to work, the company’s current biosimilar pipeline, and its expectations for how their products will perform.

Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization

July 12th 2020

Podcast

We sat down with Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare, to discuss how this program has empowered biosimilar utilization within Emory and how Emory’s initiatives could be implemented on a larger scale.

Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins

July 5th 2020

Podcast

We sat down with Jing Chao, MD, an assistant professor of medicine and metabolism, endocrinology and nutrition at the University of Washington in Seattle and one of the lead investigators of this study to discuss the findings of this study as well as how biosimilar insulins could pave the way for increased patient access.

Joe Fuhr, PhD, Discusses His Predictions for the Growing Biosimilar Market

June 28th 2020

Podcast

We sat down with Joe Fuhr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics to discuss the current state of the biosimilar landscape and what he sees going forward.

Nick Mitrokostas Discusses New Biosimilar Approval and the Outlook for 2020

June 21st 2020

Podcast

In this episode of Not So Different, we sat down with Nick Mitrokostas, an intellectual property (IP) lawyer and partner at Goodwin's IP Litigation group, to discuss how the approval of Pfizer’s pegfilgrastim biosimilar (Nyvepria) will affect the biosimilar market and what he sees for the rest of 2020.

Christine Simmon Discusses AAM Efforts for Biosimilar Legislation

June 14th 2020

Podcast

We sat down with Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the AAM, to discuss some of the advocacy changes the organization is looking to advance and their chances of approval.

Biosimilar Law Experts Discuss Potential Bills and Chances for Passage

June 7th 2020

Podcast

We sat down with Ha Kung Wong, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, to discuss potential bills to improve biosimilar uptake and their chances for passage.

April Breyer Menon Discusses 2 Potential Bills to Aid Biosimilar Uptake

May 28th 2020

Podcast

April Breyer Menon, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago, Illinois, discussed 2 pieces of legislation that have the potential to address barriers to biosimilar market entry including the Hatch-Waxman Integrity Act and the Stop Stalling Act.

Noelle Sunstrom and the Potential Growth for NeuClone

May 24th 2020

Podcast

Noelle Sunstrom, CEO and founder of NeuClone, of Redfern, Australia, discusses the company's future US market prospects and its plans to differentiate from other biosimilar developers.